Myelofibrosis (MF) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibers on which the stem cells can divide and grow.
Initially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections and a reduction of platelets can cause easy bleeding or bruising.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/myelofibrosis-market
The Myelofibrosis Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Myelofibrosis market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Myelofibrosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Myelofibrosis Market Key Facts
According to the National Organization for Rare Disorders, Primary myelofibrosis is a chronic blood disorder that affects males and females in equal numbers. It can occur at any age although it usually affects individuals more than 50 years of age. The median age at diagnosis is approximately 65. The incidence is estimated to be 1.5 cases per 100,000 people in the United States. The worldwide incidence is unknown. When primary myelofibrosis affects children, it is usually before three years of age.
According to the National Institute of Health, Primary Myelofibrosis is a rare condition that affects approximately 1 in 500,000 people worldwide.
According to the Leukemia and Lymphoma society, MF occurs in about 1.5 out of every 100,000 people in the United States annually. The disease affects both men and women and is usually diagnosed in people over the age of 50, however, MF can occur at any age.
According to a study conducted by Moular O. et al., titled, “Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union”, the incidence rate of MF across the EU ranged from 0.1 / 100,000 to 1 / 100,000 per year in 2014.
According to the Orphanet, the annual incidence of primary myelofibrosis (PMF) is approximately 1 case per 100,000 individuals, although an increased Incidence is noted in Ashkenazi Jews. Severity and prognosis are variables depending on the affected genes and symptoms.
Key Benefits of Myelofibrosis Market Report
Myelofibrosis market report provides an in-depth analysis of Myelofibrosis Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
The report will help in developing business strategies by understanding the Myelofibrosis Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
The market report covers the Myelofibrosis current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
The report provides a detailed assessment of the Myelofibrosis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
The Myelofibrosis market size shall grow during the forecast period owing to the increasing Incidence of Myelofibrosis in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Myelofibrosis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Myelofibrosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The epidemiology section covers insights about the historical and current Myelofibrosis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Myelofibrosis Epidemiology Segmentation –
Total Incident Cases of Myelofibrosis
Age-specific Incident Cases of Myelofibrosis
Type-specific Incident Cases of Myelofibrosis
Diagnosed and Diagnosed and Treatable cases of Myelofibrosis
Myelofibrosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myelofibrosis market or expected to get launched in the market during the study period. The analysis covers Myelofibrosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Myelofibrosis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Myelofibrosis market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Myelofibrosis emerging therapies.
The dynamics of the Myelofibrosis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period.
Suzhou Zelgen Biopharmaceuticals
And many others.
Myelofibrosis Therapies covered in the report include:
Jaktinib hydrochloride tablets
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Myelofibrosis Competitive Intelligence Analysis
4. Myelofibrosis Market Overview at a Glance
5. Myelofibrosis Disease Background and Overview
6. Myelofibrosis Patient Journey
7. Myelofibrosis Epidemiology and Patient Population
8. Myelofibrosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Myelofibrosis Unmet Needs
10. Key Endpoints of Myelofibrosis Treatment
11. Myelofibrosis Marketed Products
12. Myelofibrosis Emerging Therapies
13. Myelofibrosis Seven Major Market Analysis
14. Attribute Analysis
15. Myelofibrosis Market Outlook (7 major markets)
16. Myelofibrosis Access and Reimbursement Overview
17. KOL Views on the Myelofibrosis Market.
18. Myelofibrosis Market Drivers
19. Myelofibrosis Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/myelofibrosis-market
Pacemakers Pipeline Key Companies
According to a research article by (Hao et al., 2015), “there are more than 3 million functioning permanent pacemakers and about 600,000 pacemakers that are implanted each year worldwide”. As per Delveinsight’s estimate, 90% of the Pacemaker devices available in the market are implantable, whereas only 10% of the pacemaker devices can be used externally. There is a huge scope of growth in the Pacemaker Market, as 92% of the devices are currently in the marketed stage”. To tap the market share, companies such as Abbott, Boston Scientific, AtaCor Medical, MicroPort Orthopedics, NuVascular Technologies, Leonhardt Ventures are diligently working in the Pacemaker Market. For more details, visit: Pacemaker Pipeline Devices
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States